Amerigen Pharmaceuticals, Forest Laboratories deal

Forest invested in Amerigen's early stage generics development program in exchange for royalties on U.S. sales and an option to acquire rights to commercialize the products in Latin America. Amerigen will use its formulation expertise to develop the products and then commercialize them in the U.S. and is eligible to receive undisclosed milestones from Forest. Amerigen could not be reached, and Forest declined to provide details, but did say that the deal is unrelated to a July settlement agreement. Forest also said the products covered by the deal are not generic versions of Forest drugs. ...